WuXi AppTec Co., Ltd. (SHA:603259)
160.21
-1.13 (-0.70%)
Aug 11, 2026, 3:00 PM CST
WuXi AppTec Employees
WuXi AppTec had 35,584 employees as of June 30, 2026. The number of employees increased by 1,750 or 5.17% since the number was reported on December 31, 2025.
Employees
35,584
Change
1,750
Growth
5.17%
Revenue / Employee
1.45M CNY
Profits / Employee
611.81K CNY
Market Cap
478.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 35,584 | 1,750 | 5.17% |
| Dec 31, 2025 | 33,834 | -5,580 | -14.16% |
| Dec 31, 2024 | 39,414 | -1,702 | -4.14% |
| Dec 31, 2023 | 41,116 | -3,245 | -7.31% |
| Dec 31, 2022 | 44,361 | 9,449 | 27.07% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Hangzhou Tigermed Consulting | 11,130 |
| Guangzhou Kingmed Diagnostics Group | 9,529 |
| Dian Diagnostics Group | 7,462 |
| BGI Genomics | 3,580 |
| Maccura Biotechnology Co.Ltd | 2,946 |
| Shanghai Runda Medical Technology | 2,945 |
| Joinn Laboratories(China)Co.,Ltd. | 2,649 |
| Shanghai Labway Clinical Laboratory | 1,245 |
WuXi AppTec News
- 3 days ago - Judge blocks US decision to add WuXi to list of firms tied to Chinese military - Reuters
- 8 days ago - WuXi AppTec Quarterly report: Q2 2026 - Filings
- 2 months ago - WuXi AppTec files complaint against U.S. DoD for linking it to Chinese military - Reuters
- 3 months ago - WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index - PRNewsWire
- 3 months ago - WuXi AppTec Delivers Strong Revenue and Profit Growth in Q1 2026 - PRNewsWire
- 3 months ago - WuXi AppTec Slides: Q1 2026 - Filings
- 3 months ago - WuXi AppTec Quarterly report: Q1 2026 - Filings
- 5 months ago - WuXi AppTec Earnings Call Transcript: H2 2025 - Transcripts